Prescription Medicines
Acer Cap.
- Product Category
- Anti-inflammatory painkiller that improves gastrointestinal disorders
- Active Ingredients
- Aceclofenac
- Appearance
- Hard capsule containing white powder, dark blue at the top and light yellow at the bottom.
- Reimbursement Code
- 648101510
01 / 02
1. Composition and Strength
- Active ingredient: Aceclofenac (EP)----100mg
- Additives (tar colorant): Red No. 3, Blue No. 1, Yellow No. 5, Yellow No. 203
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: magnesium stearate, colloidal silicon dioxide, capsules
2. Effectiveness
Pain due to rheumatoid arthritis, ankylosing spondylitis, osteoarthritis (degenerative arthritis), periarthritis of the scapulohumeral joint, toothache, inflammation occurring after trauma, back pain, sciatica, and non-articular rheumatism.
3. Dosage and dosage
○ Adults: Take aceclofenac, 100 mg once, twice a day, every 12 hours.
○ Patients with hepatic impairment: The initial dose is 100 mg per day.
Take this medicine as is, without chewing or crushing it.
Increase or decrease appropriately depending on symptoms.
To minimize cardiovascular adverse reactions from this drug, it should be administered at the lowest effective dose and for the shortest period of time.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk and cerebrovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. Patients with congestive heart failure [New York Heart Association (NYHA) I] and significant risk factors for cardiovascular disease (e.g., hypertension, hyperlipidemia, diabetes, smoking) should begin treatment with this drug after careful review. Since the risk of cardiovascular disease due to administration of this drug may increase depending on the dose and period of administration, it should be administered at the lowest effective daily dose for the shortest possible period. The patient's need for symptom relief and response to treatment should be reassessed periodically.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about the signs and/or symptoms of serious cardiovascular toxicity and the measures to be taken if these symptoms occur.
This drug should be administered with particular caution and under strict medical supervision to patients with a history of cerebrovascular hemorrhage.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. Do not administer to the following patients (cases).
1) Patients with active peptic ulcer/bleeding or a history thereof
2) Patients with hypersensitivity to this drug, its components, or some drugs in the same class (diclofenac)
3) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs.)
4) Asthma patients who may have an increased risk of asthma or cause hives or acute rhinitis due to aspirin or other drugs that inhibit prostaglandin synthase.
5) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
6) Patients with severe heart failure and congestive heart failure (NYHA Ⅱ~Ⅳ), ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease
7) Patients with severe renal impairment
8) Patients with severe hepatic impairment
9) Patients with a history of gastrointestinal bleeding or perforation due to previous treatment with non-steroidal anti-inflammatory drugs
10) Pregnant women in the last trimester of pregnancy
11) Nursing mothers
12) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
13) Patients with bleeding or blood coagulation disorders
3. Administer with caution to the following patients.
1) Patients with renal impairment or its history
2) Patients with fluid retention or heart failure
3) Patients taking diuretics or ACE inhibitors
4) Patients in recovery after surgical treatment
5) Elderly people
6) Patients with bronchial asthma or a history of it (bronchospasm has been reported due to administration of non-steroidal anti-inflammatory drugs).
7) Patients with congenital disorders of porphyrin metabolism
8) Patients with high blood pressure
9) Patients with hepatic impairment or its history
10) Patients who have had digestive ulcers due to past long-term administration of non-steroidal anti-inflammatory drugs, and who require long-term administration of this drug and are concurrently receiving peptic ulcer treatment with misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
11) Women in the early or middle stages of pregnancy, women who may be pregnant, or women planning to become pregnant
12) Patients receiving anticoagulants
4. Adverse reactions
Most commonly, gastrointestinal adverse reactions, dizziness, and abnormal liver enzyme levels were reported. Rarely, adverse skin reactions including itching and rash
1) Blood and lymphatic system: Rarely anemia, very rarely leukopenia, thrombocytopenia, neutropenia, hemolytic anemia, aplastic anemia, agranulocytosis.
2) Hypersensitivity reaction: rarely shock, anaphylactic reaction
3) Metabolism: Very rare hyperkalemia
4) Mental nervous system: Frequently dizziness, very rarely depression, strange dreams, insomnia
5) Sensory system: Rarely visual impairment, optic neuritis, very rare paresthesia, tremor, drowsiness, headache, taste disorder, neck stiffness, fever or disorientation, confusion, hallucinations, tinnitus, malaise.
6) Circulatory system: In very rare cases, palpitations and facial flushing may occur. Hypertension and heart failure have been reported in relation to non-steroidal anti-inflammatory drugs.
Because aceclofenac is structurally similar to diclofenac and is metabolized to diclofenac, many clinical and epidemiological data have shown an increased risk of arterial thrombotic events (myocardial infarction or stroke, especially with high doses and long-term treatment). Additionally, epidemiological data showed an increased risk of acute coronary syndrome and myocardial infarction associated with aceclofenac administration.
7) Respiratory system: Rarely, dyspnea, very rarely, bronchospasm, stridor.
8) Digestive system: Gastrointestinal adverse reactions are most commonly observed. Peptic ulcers, perforation, or gastrointestinal bleeding may occur, sometimes in serious cases, and are more serious in elderly people. Frequent indigestion, abdominal pain, nausea, diarrhea Occasionally bloating, gastritis, constipation, vomiting, mouth ulcers Rarely melena, very rarely stomatitis, hematemesis, pancreatitis, exacerbation of colitis, Crohn's disease
9) Liver: Very rarely, hepatitis, jaundice, elevation of AST, ALT, ALP
10) Skin: Occasionally, itching, rash, redness, dermatitis, urticaria, rarely facial edema, and very rarely, blistering reactions including purpura, bullous dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome) occur. Photosensitivity reaction, hair loss
11) Kidney: Kidney failure, nephrotic syndrome
12) Local reactions: edema, fatigue, leg cramps
13) Others: Frequent elevation of liver enzymes, occasional elevation of blood urea or creatinine, weight gain, increased enuresis, aseptic meningitis (especially autoimmune diseases such as systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)
14) The following adverse reactions are added according to analysis and evaluation of domestic side effect report data.
· Skin: Angioedema
· Others: peripheral edema, edema around the eyes
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
3) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
4) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
5) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal failure, liver failure, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
7) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
8) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. This drug should not be administered to patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants.
9) When using for chronic diseases, consider the following:
(1) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should regularly undergo complete blood count (CBC) and physicochemical tests. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
(2) Treatments other than drug therapy are also considered.
10) When using for acute diseases, consider the following:
(1) Administer considering the degree of acute inflammation, pain, and fever.
(2) In principle, long-term administration of the same drug should be avoided.
(3) If there is a causal treatment, implement it.
11) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
12) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
13) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
14) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
15) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
16) Patients who feel dizziness or other central nervous system disorders (drowsiness, fatigue, visual disturbances) should not drive or operate dangerous machinery, and avoid environments that require special attention.
17) It may reduce a woman's ability to conceive, so women planning to become pregnant are not recommended to take it. Temporary infertility has been reported in women taking NSAIDs for long periods of time. It is recommended that women who have difficulty conceiving or are undergoing infertility treatment discontinue taking this drug.
18) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
6. Interaction
1) If the patient is taking other drugs, especially digoxin, anticoagulants, oral antidiabetic agents, or diuretics, consult a doctor.
2) ACE inhibitors or angiotensin II receptor antagonists: There have been reports that the antihypertensive effect of ACE inhibitors or angiotensin II receptor antagonists may be reduced by non-steroidal anti-inflammatory analgesics, so this interaction should be kept in mind when coadministering this drug with ACE inhibitors or angiotensin II receptor antagonists.
3) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic reactions associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
4) Diuretics
(1) Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
(2) When used in combination with potassium-sparing diuretics, serum potassium concentration may increase, so blood potassium concentration should be monitored. It is not known whether it affects blood pressure control when used in combination with bendrofluzide, but interactions with other diuretics cannot be ruled out.
5) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering NSAIDs and lithium, signs of lithium toxicity should be carefully observed.
6) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered together with high doses of methotrexate (more than 15 mg/week) used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate.
7) Coumarin anticoagulants (warfarin, etc.): Warfarin and NSAIDs may have a synergistic effect on gastrointestinal bleeding, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
8) Do not use in combination with other non-steroidal anti-inflammatory drugs (including selective COX-2 inhibitors) as the risk of adverse reactions may increase.
9) Since this drug is metabolized by CYP2C9, there is a possibility of pharmacokinetic interaction with phenytoin, cimetidine, miconazole, sulfafenazole, amiodarone, tolbutamide, and phenylbutazone.
10) Cardiac glycosides: Non-steroidal anti-inflammatory drugs can worsen heart failure by decreasing the glomerular filtration rate and increasing the blood concentration of glycosides.
11) Mifepristone: Non-steroidal anti-inflammatory drugs should not be administered for 8 to 12 days after taking mifepristone because they reduce the effectiveness of mifepristone.
12) Quinolone antibiotics: Be careful because there is animal testing data that shows that the risk of convulsions may increase when administered in combination with non-steroidal anti-inflammatory analgesics.
13) Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): The risk of gastrointestinal bleeding may increase when used together with this drug.
14) Cyclosporine and tacrolimus: The risk of nephrotoxicity may increase when administered concurrently with non-steroidal anti-inflammatory drugs.
15) Zidovudine: Hematological toxicity may increase when administered in combination with non-steroidal anti-inflammatory drugs. There is evidence that coadministration of zidovudine and ibuprofen in patients with HIV(+) hemophilia increases the risk of hemarthrosis and hematoma.
16) Antidiabetic agent: Clinical results showed that diclofenac does not affect the clinical effect of oral hypoglycemic agents when used in combination with oral hypoglycemic agents. However, since hypoglycemic and hyperglycemic effects were rarely reported during treatment with this drug, the dose of hypoglycemic medications must be adjusted.
17) Corticosteroids: When used together with this drug, the risk of gastrointestinal ulcers or bleeding may increase.
7. Administration to pregnant and lactating women
1) There is no clinical data on administering this drug to pregnant women. Like other non-steroidal anti-inflammatory analgesics, this drug may cause premature closure of the ductus arteriosus of the fetus when administered at the end of pregnancy. Therefore, it should be carefully administered to women planning to become pregnant or pregnant women in the early and middle trimester of pregnancy with the minimum dose and duration of use, and should not be administered to pregnant women in the last trimester of pregnancy.
2) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after approximately 20 weeks of pregnancy may cause abnormalities in fetal renal function, resulting in oligohydramnios and, in some cases, neonatal renal failure. Although oligohydramnios has been uncommonly reported within 48 hours of starting nonsteroidal anti-inflammatory drugs (NSAIDs), this side effect usually appears days to weeks after administration. Oligohydramnios is usually reversible upon discontinuation of treatment, but this is not always the case. If oligohydramnios persists, complications (e.g., limb contractures and delayed lung maturation) may occur. Some post-marketing cases of impaired neonatal renal function have required invasive procedures such as exchange transfusion or dialysis. If administration of this drug is necessary during the 20th to 30th week of pregnancy, the lowest effective dose should be used for the shortest period of time and if the administration time exceeds 48 hours, ultrasound monitoring of amniotic fluid should be considered. If oligohydramnios occurs, discontinue this drug and follow-up according to medical guidelines.
3) Safety for pregnant women has not been sufficiently established based on the data known to date. In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased fetal survival rate.
4) Based on the data known to date, safety for nursing mothers has not been sufficiently established, and it is not known whether this drug is secreted into human breast milk. However, many drugs not only pass into breast milk, but if they do so, there is concern that serious adverse reactions may occur in infants. Therefore, considering the importance of drug administration to nursing mothers, breastfeeding or drug administration should be discontinued.
8. Administration to children
No set dosage or indications have been established for children (the safety and effectiveness of this drug in children and adolescents have not been established).
9. Administration to elderly people
In elderly people, the frequency of adverse reactions to non-steroidal anti-inflammatory drugs, especially gastrointestinal bleeding and perforation, increases. Therefore, as with other non-steroidal anti-inflammatory drugs, caution should be exercised when administering this drug to the elderly.
10. Treatment in case of overdose
The typical symptoms of overdose are not known, but in case of accidental overdose, treatment should be taken according to the symptoms observed, and be prepared for gastrointestinal irritation, low blood pressure, respiratory depression, and convulsions.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 100 capsules/bottle
7. Expiration date
36 months from date of manufacture
- Active ingredient: Aceclofenac (EP)----100mg
- Additives (tar colorant): Red No. 3, Blue No. 1, Yellow No. 5, Yellow No. 203
- Additives (animal-derived ingredients): Anhydrous lactose (cow, milk)
- Other additives: magnesium stearate, colloidal silicon dioxide, capsules
2. Effectiveness
Pain due to rheumatoid arthritis, ankylosing spondylitis, osteoarthritis (degenerative arthritis), periarthritis of the scapulohumeral joint, toothache, inflammation occurring after trauma, back pain, sciatica, and non-articular rheumatism.
3. Dosage and dosage
○ Adults: Take aceclofenac, 100 mg once, twice a day, every 12 hours.
○ Patients with hepatic impairment: The initial dose is 100 mg per day.
Take this medicine as is, without chewing or crushing it.
Increase or decrease appropriately depending on symptoms.
To minimize cardiovascular adverse reactions from this drug, it should be administered at the lowest effective dose and for the shortest period of time.
4. Precautions for use
1. Warning
1) If a person who regularly drinks three or more glasses of alcohol a day needs to take this medicine or another antipyretic analgesic, he or she must consult a doctor or pharmacist. If these people take this medicine, it may cause gastrointestinal bleeding.
2) Cardiovascular risk and cerebrovascular risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious cardiovascular thrombotic reactions, myocardial infarction and stroke, which can be fatal. Patients with congestive heart failure [New York Heart Association (NYHA) I] and significant risk factors for cardiovascular disease (e.g., hypertension, hyperlipidemia, diabetes, smoking) should begin treatment with this drug after careful review. Since the risk of cardiovascular disease due to administration of this drug may increase depending on the dose and period of administration, it should be administered at the lowest effective daily dose for the shortest possible period. The patient's need for symptom relief and response to treatment should be reassessed periodically.
Physicians and patients must carefully monitor the development of these cardiovascular symptoms, even if there is no history of cardiovascular disease. Patients should be informed in advance about the signs and/or symptoms of serious cardiovascular toxicity and the measures to be taken if these symptoms occur.
This drug should be administered with particular caution and under strict medical supervision to patients with a history of cerebrovascular hemorrhage.
3) Gastrointestinal risk: Non-steroidal anti-inflammatory drugs, including this drug, may increase the risk of serious gastrointestinal adverse reactions, including gastric or intestinal bleeding, ulceration, and perforation, which may be fatal. These adverse reactions may occur without warning symptoms during the administration period. Older adults may be at greater risk for serious gastrointestinal adverse events.
The longer the administration period, the more likely it is that serious gastrointestinal side effects will occur, but this risk cannot be completely ruled out during short-term administration.
While administering this drug, patients should be carefully monitored for symptoms and signs of gastrointestinal ulcers or bleeding, and if serious adverse gastrointestinal reactions are suspected, additional evaluation and treatment should be performed immediately. Discontinuing the administration of non-steroidal anti-inflammatory drugs until severe gastrointestinal side effects are completely ruled out can also be a treatment option. For patients at high risk, alternative treatments unrelated to NSAIDs should be considered.
2. Do not administer to the following patients (cases).
1) Patients with active peptic ulcer/bleeding or a history thereof
2) Patients with hypersensitivity to this drug, its components, or some drugs in the same class (diclofenac)
3) Patients with a history of asthma, urticaria, or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs (including COX-2 inhibitors) (In these patients, severe and fatal anaphylactoid reactions have been rarely reported after administration of non-steroidal anti-inflammatory drugs.)
4) Asthma patients who may have an increased risk of asthma or cause hives or acute rhinitis due to aspirin or other drugs that inhibit prostaglandin synthase.
5) Treatment of pain occurring before and after coronary artery bypass surgery (CABG)
6) Patients with severe heart failure and congestive heart failure (NYHA Ⅱ~Ⅳ), ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease
7) Patients with severe renal impairment
8) Patients with severe hepatic impairment
9) Patients with a history of gastrointestinal bleeding or perforation due to previous treatment with non-steroidal anti-inflammatory drugs
10) Pregnant women in the last trimester of pregnancy
11) Nursing mothers
12) Patients with inflammatory bowel disease such as Crohn's disease or ulcerative colitis
13) Patients with bleeding or blood coagulation disorders
3. Administer with caution to the following patients.
1) Patients with renal impairment or its history
2) Patients with fluid retention or heart failure
3) Patients taking diuretics or ACE inhibitors
4) Patients in recovery after surgical treatment
5) Elderly people
6) Patients with bronchial asthma or a history of it (bronchospasm has been reported due to administration of non-steroidal anti-inflammatory drugs).
7) Patients with congenital disorders of porphyrin metabolism
8) Patients with high blood pressure
9) Patients with hepatic impairment or its history
10) Patients who have had digestive ulcers due to past long-term administration of non-steroidal anti-inflammatory drugs, and who require long-term administration of this drug and are concurrently receiving peptic ulcer treatment with misoprostol (some peptic ulcers are resistant to treatment with misoprostol, so sufficiently observe the progress while taking this drug).
11) Women in the early or middle stages of pregnancy, women who may be pregnant, or women planning to become pregnant
12) Patients receiving anticoagulants
4. Adverse reactions
Most commonly, gastrointestinal adverse reactions, dizziness, and abnormal liver enzyme levels were reported. Rarely, adverse skin reactions including itching and rash
1) Blood and lymphatic system: Rarely anemia, very rarely leukopenia, thrombocytopenia, neutropenia, hemolytic anemia, aplastic anemia, agranulocytosis.
2) Hypersensitivity reaction: rarely shock, anaphylactic reaction
3) Metabolism: Very rare hyperkalemia
4) Mental nervous system: Frequently dizziness, very rarely depression, strange dreams, insomnia
5) Sensory system: Rarely visual impairment, optic neuritis, very rare paresthesia, tremor, drowsiness, headache, taste disorder, neck stiffness, fever or disorientation, confusion, hallucinations, tinnitus, malaise.
6) Circulatory system: In very rare cases, palpitations and facial flushing may occur. Hypertension and heart failure have been reported in relation to non-steroidal anti-inflammatory drugs.
Because aceclofenac is structurally similar to diclofenac and is metabolized to diclofenac, many clinical and epidemiological data have shown an increased risk of arterial thrombotic events (myocardial infarction or stroke, especially with high doses and long-term treatment). Additionally, epidemiological data showed an increased risk of acute coronary syndrome and myocardial infarction associated with aceclofenac administration.
7) Respiratory system: Rarely, dyspnea, very rarely, bronchospasm, stridor.
8) Digestive system: Gastrointestinal adverse reactions are most commonly observed. Peptic ulcers, perforation, or gastrointestinal bleeding may occur, sometimes in serious cases, and are more serious in elderly people. Frequent indigestion, abdominal pain, nausea, diarrhea Occasionally bloating, gastritis, constipation, vomiting, mouth ulcers Rarely melena, very rarely stomatitis, hematemesis, pancreatitis, exacerbation of colitis, Crohn's disease
9) Liver: Very rarely, hepatitis, jaundice, elevation of AST, ALT, ALP
10) Skin: Occasionally, itching, rash, redness, dermatitis, urticaria, rarely facial edema, and very rarely, blistering reactions including purpura, bullous dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome) occur. Photosensitivity reaction, hair loss
11) Kidney: Kidney failure, nephrotic syndrome
12) Local reactions: edema, fatigue, leg cramps
13) Others: Frequent elevation of liver enzymes, occasional elevation of blood urea or creatinine, weight gain, increased enuresis, aseptic meningitis (especially autoimmune diseases such as systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD)
14) The following adverse reactions are added according to analysis and evaluation of domestic side effect report data.
· Skin: Angioedema
· Others: peripheral edema, edema around the eyes
5. General precautions
1) Before administering this drug, the potential risks and benefits of this drug and other alternative treatments should be considered. This drug is administered at the lowest effective dose for the shortest possible period consistent with the treatment goals of each patient.
2) Gastrointestinal adverse reactions: Extreme caution should be exercised when prescribing non-steroidal anti-inflammatory drugs, including this drug, to patients with a history of ulcerative disease or gastrointestinal bleeding. In patients with a history of peptic ulcer disease and/or gastrointestinal bleeding, the risk of gastrointestinal bleeding increased more than 10 times when taking nonsteroidal anti-inflammatory drugs compared to patients without these risk factors. Other risk factors that increase gastrointestinal bleeding include concurrent use of oral corticosteroids or anticoagulants, long-term use of nonsteroidal anti-inflammatory drugs, alcohol consumption, old age, and poor health. Since most spontaneous reports of fatal gastrointestinal adverse reactions are in elderly and frail patients, special caution should be exercised when administering this drug to these patients.
3) High blood pressure: Non-steroidal anti-inflammatory drugs, including this drug, may cause high blood pressure or worsen existing high blood pressure, which may increase the incidence of adverse cardiovascular events. Patients taking thiazide diuretics or loop diuretics may have a decreased response to these therapies when taking NSAIDs. Non-steroidal anti-inflammatory drugs, including this drug, should be administered with caution in patients with hypertension. Blood pressure should be closely monitored at the beginning and during treatment of this drug.
4) Congestive heart failure and edema: Fluid retention and edema have been observed in some patients taking non-steroidal anti-inflammatory drugs, including this drug. This drug should be administered with caution in patients with fluid retention or heart failure.
5) Long-term use of non-steroidal anti-inflammatory drugs may cause kidney papillary necrosis or other kidney damage. In addition, since the role of prostaglandins is important in maintaining renal blood flow, special caution is required in patients with heart failure, renal failure, liver failure, patients taking diuretics or ACE inhibitors, and the elderly. When medication is stopped, most cases return to their pre-treatment state.
6) Advanced renal disease: No controlled clinical trials have been conducted on the use of this drug in patients with advanced renal disease. Therefore, administration of this drug is not recommended for patients with advanced renal disease. If treatment with this drug is to be initiated, the patient's renal function should be closely monitored.
7) Administration of non-steroidal anti-inflammatory drugs, including this drug, may result in an increase in liver function levels. These abnormal test values may worsen, remain unchanged, or be temporary as treatment continues. Additionally, serious liver-related adverse reactions, including jaundice, fatal fulminant hepatitis, liver necrosis, and liver failure (some of which were fatal), have been reported rarely with the administration of non-steroidal anti-inflammatory drugs, including this drug.
For patients with symptoms and/or signs suggestive of liver function abnormality or abnormal liver function test results, carefully observe whether liver function deteriorates during the treatment period, and if clinical symptoms or systemic signs related to liver disease (e.g. eosinophilia, rash) appear, administration of this drug should be discontinued.
8) Since anemia may occur due to administration of non-steroidal anti-inflammatory drugs, including this drug, a hemoglobin level or hematocrit test should be performed if symptoms or signs of anemia appear due to long-term administration of this drug.
Non-steroidal anti-inflammatory drugs have been found to inhibit platelet aggregation and prolong bleeding time in some patients. Unlike aspirin, the effects of this drug on platelet function are relatively small, short-lived, and reversible. This drug should not be administered to patients who may be adversely affected by altered platelet function, such as those with coagulation-related disorders or those taking anticoagulants.
9) When using for chronic diseases, consider the following:
(1) Patients taking non-steroidal anti-inflammatory drugs for a long period of time should regularly undergo complete blood count (CBC) and physicochemical tests. If clinical symptoms or systemic signs (e.g., eosinophilia, rash) related to liver or renal disease develop, or if abnormal liver or renal function test results persist or worsen, treatment with this drug should be discontinued.
(2) Treatments other than drug therapy are also considered.
10) When using for acute diseases, consider the following:
(1) Administer considering the degree of acute inflammation, pain, and fever.
(2) In principle, long-term administration of the same drug should be avoided.
(3) If there is a causal treatment, implement it.
11) Anaphylactoid reaction: Like other non-steroidal anti-inflammatory drugs, anaphylactoid reaction can occur even in patients who have not been exposed to the drug. This symptom complex typically occurs in patients with asthma who present with severe, potentially fatal bronchospasm with or without nasal polyps following administration of aspirin or other NSAIDs. If such an anaphylactic reaction occurs, emergency treatment must be administered.
12) Skin reactions: This drug may cause serious skin adverse reactions such as exfoliative dermatitis, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome), which can be fatal. These serious adverse reactions may occur without warning symptoms. In most cases, these adverse reactions occur within the first month of administration. Patients should be aware of serious skin signs and symptoms and should discontinue medication at the first sign or sign of skin rash or other hypersensitivity reaction.
13) Some asthma patients may react sensitively to aspirin. Aspirin use in patients with aspirin-sensitive asthma may be associated with severe bronchospasm, which can be fatal. Cross-reactivity, including bronchospasm, between aspirin and other NSAIDs has been reported in these aspirin-sensitive patients. Therefore, this drug should not be administered to aspirin-sensitive patients and should be used with caution in asthma patients.
14) This drug cannot be used as a replacement for corticosteroid preparations or as a drug to treat corticoid deficiency. Abrupt discontinuation of corticosteroid administration may result in worsening of corticosteroid-responsive disease. If this drug is to be administered to a patient who has been taking corticosteroids for a long period of time, the dose should be gradually reduced.
15) Due to the pharmacological properties of this drug, it may suppress other symptoms and signs of inflammation, delaying the diagnosis of infectious complications under painful and non-infectious conditions.
16) Patients who feel dizziness or other central nervous system disorders (drowsiness, fatigue, visual disturbances) should not drive or operate dangerous machinery, and avoid environments that require special attention.
17) It may reduce a woman's ability to conceive, so women planning to become pregnant are not recommended to take it. Temporary infertility has been reported in women taking NSAIDs for long periods of time. It is recommended that women who have difficulty conceiving or are undergoing infertility treatment discontinue taking this drug.
18) Please note that treatment with anti-inflammatory painkillers is symptomatic treatment, not causative treatment.
6. Interaction
1) If the patient is taking other drugs, especially digoxin, anticoagulants, oral antidiabetic agents, or diuretics, consult a doctor.
2) ACE inhibitors or angiotensin II receptor antagonists: There have been reports that the antihypertensive effect of ACE inhibitors or angiotensin II receptor antagonists may be reduced by non-steroidal anti-inflammatory analgesics, so this interaction should be kept in mind when coadministering this drug with ACE inhibitors or angiotensin II receptor antagonists.
3) Aspirin: There is no consistent evidence that combined use with aspirin can reduce the risk of serious cardiovascular thrombotic reactions associated with the use of nonsteroidal anti-inflammatory drugs. As with other non-steroidal anti-inflammatory drugs, the combined use of this drug and aspirin may increase the risk of serious gastrointestinal adverse reactions, so the combined use of the two drugs is generally not recommended.
4) Diuretics
(1) Clinical trials and post-marketing studies have confirmed that the natriuretic effect of furosemide and thiazide diuretics may be reduced in some patients due to this drug's inhibition of prostaglandin synthesis in the kidneys. Patients should be closely monitored for signs of renal failure during concurrent use of these drugs and nonsteroidal anti-inflammatory drugs.
(2) When used in combination with potassium-sparing diuretics, serum potassium concentration may increase, so blood potassium concentration should be monitored. It is not known whether it affects blood pressure control when used in combination with bendrofluzide, but interactions with other diuretics cannot be ruled out.
5) Lithium: Non-steroidal anti-inflammatory drugs can increase serum lithium concentration and reduce renal clearance of lithium by inhibiting prostaglandin synthesis in the kidney. Therefore, when co-administering NSAIDs and lithium, signs of lithium toxicity should be carefully observed.
6) Methotrexate: Concurrent administration with non-steroidal anti-inflammatory drugs delays the excretion of methotrexate from the renal tubules, which may increase the fatal hematological toxicity of methotrexate. Therefore, it should not be administered together with high doses of methotrexate (more than 15 mg/week) used in anticancer therapy, and must be administered with caution when administered in combination with low doses of methotrexate.
7) Coumarin anticoagulants (warfarin, etc.): Warfarin and NSAIDs may have a synergistic effect on gastrointestinal bleeding, so patients who use both drugs together may have an increased risk of severe gastrointestinal bleeding compared to those who take the two drugs alone.
8) Do not use in combination with other non-steroidal anti-inflammatory drugs (including selective COX-2 inhibitors) as the risk of adverse reactions may increase.
9) Since this drug is metabolized by CYP2C9, there is a possibility of pharmacokinetic interaction with phenytoin, cimetidine, miconazole, sulfafenazole, amiodarone, tolbutamide, and phenylbutazone.
10) Cardiac glycosides: Non-steroidal anti-inflammatory drugs can worsen heart failure by decreasing the glomerular filtration rate and increasing the blood concentration of glycosides.
11) Mifepristone: Non-steroidal anti-inflammatory drugs should not be administered for 8 to 12 days after taking mifepristone because they reduce the effectiveness of mifepristone.
12) Quinolone antibiotics: Be careful because there is animal testing data that shows that the risk of convulsions may increase when administered in combination with non-steroidal anti-inflammatory analgesics.
13) Antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): The risk of gastrointestinal bleeding may increase when used together with this drug.
14) Cyclosporine and tacrolimus: The risk of nephrotoxicity may increase when administered concurrently with non-steroidal anti-inflammatory drugs.
15) Zidovudine: Hematological toxicity may increase when administered in combination with non-steroidal anti-inflammatory drugs. There is evidence that coadministration of zidovudine and ibuprofen in patients with HIV(+) hemophilia increases the risk of hemarthrosis and hematoma.
16) Antidiabetic agent: Clinical results showed that diclofenac does not affect the clinical effect of oral hypoglycemic agents when used in combination with oral hypoglycemic agents. However, since hypoglycemic and hyperglycemic effects were rarely reported during treatment with this drug, the dose of hypoglycemic medications must be adjusted.
17) Corticosteroids: When used together with this drug, the risk of gastrointestinal ulcers or bleeding may increase.
7. Administration to pregnant and lactating women
1) There is no clinical data on administering this drug to pregnant women. Like other non-steroidal anti-inflammatory analgesics, this drug may cause premature closure of the ductus arteriosus of the fetus when administered at the end of pregnancy. Therefore, it should be carefully administered to women planning to become pregnant or pregnant women in the early and middle trimester of pregnancy with the minimum dose and duration of use, and should not be administered to pregnant women in the last trimester of pregnancy.
2) Use of non-steroidal anti-inflammatory drugs (NSAIDs), including this drug, after approximately 20 weeks of pregnancy may cause abnormalities in fetal renal function, resulting in oligohydramnios and, in some cases, neonatal renal failure. Although oligohydramnios has been uncommonly reported within 48 hours of starting nonsteroidal anti-inflammatory drugs (NSAIDs), this side effect usually appears days to weeks after administration. Oligohydramnios is usually reversible upon discontinuation of treatment, but this is not always the case. If oligohydramnios persists, complications (e.g., limb contractures and delayed lung maturation) may occur. Some post-marketing cases of impaired neonatal renal function have required invasive procedures such as exchange transfusion or dialysis. If administration of this drug is necessary during the 20th to 30th week of pregnancy, the lowest effective dose should be used for the shortest period of time and if the administration time exceeds 48 hours, ultrasound monitoring of amniotic fluid should be considered. If oligohydramnios occurs, discontinue this drug and follow-up according to medical guidelines.
3) Safety for pregnant women has not been sufficiently established based on the data known to date. In experiments on rats, non-steroidal anti-inflammatory drugs, like other drugs that inhibit prostaglandin synthesis, increased the frequency of dystocia, delayed delivery, and decreased fetal survival rate.
4) Based on the data known to date, safety for nursing mothers has not been sufficiently established, and it is not known whether this drug is secreted into human breast milk. However, many drugs not only pass into breast milk, but if they do so, there is concern that serious adverse reactions may occur in infants. Therefore, considering the importance of drug administration to nursing mothers, breastfeeding or drug administration should be discontinued.
8. Administration to children
No set dosage or indications have been established for children (the safety and effectiveness of this drug in children and adolescents have not been established).
9. Administration to elderly people
In elderly people, the frequency of adverse reactions to non-steroidal anti-inflammatory drugs, especially gastrointestinal bleeding and perforation, increases. Therefore, as with other non-steroidal anti-inflammatory drugs, caution should be exercised when administering this drug to the elderly.
10. Treatment in case of overdose
The typical symptoms of overdose are not known, but in case of accidental overdose, treatment should be taken according to the symptoms observed, and be prepared for gastrointestinal irritation, low blood pressure, respiratory depression, and convulsions.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle, 100 capsules/bottle
7. Expiration date
36 months from date of manufacture
Product Updates
Total 6items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 6 | Acer Cap. | Precautions for use | 2024.05.22 | PDFAcer Capsule_Precautions for use.pdf |
| 5 | Acer Cap. | Acer capsule (dosage, precautions for use) | 2015.07.24 | HWPAceclofenac single agent_Dosage and precautions for use.hwp |
| 4 | Acer Cap. | Acer Capsule (Precautions for use) | 2013.09.13 | HWPPrecautions for use of aceclofenac single agent (tablet, capsule) |
| 3 | Acer Cap. | Acer Capsule (effectiveness, dosage, directions for use... | 2011.12.29 | HWPAcer Capsule Effectiveness_Usage_Dosage_Precautions for use.hwp |
| 2 | Acer Cap. | Acer Capsule (Precautions for use) | 2011.10.28 | HWPAcer Capsule (Precautions for use).hwp |
| 1 | Acer Cap. | Acer Capsule (Precautions for use) | 2008.02.01 | HWP9. Change information - Acer capsule (precautions for use) change.hwp |